The study is expected to begin in the first quarter of 2027 & enrol around 1,000 patients in Brazil, Malaysia & Thailand. SII is also conducting a separate Phase III trial in India.
US's FluMist can now be administered by a healthcare provider or by recipient or caregiver aged 18 or above. India's Nasovac S4 faces hurdles like cost, availability & low acceptance.
MenFive targets 5 causes of meningococcal meningitis, a bacterial infection that can kill within hours. It can cause severe brain damage and sepsis, and is fatal in 50% cases if untreated.
Pune-based SII has got the go-ahead from the Drugs Controller General of India to market the vaccine. Cervical cancer is one of the leading causes of female cancer mortality worldwide.
Cervical cancer in India is the 2nd most frequent cancer among women between 15-44 years of age. Currently, India is fully dependent on foreign manufacturers for the vaccine.
SII's Director of Government and Regulatory Affairs is learnt to have recently communicated to Union Health Ministry that it has a manufactured stock of 24,89,15,000 Covishield doses.
July could be busiest month for India’s diplomatic establishment as Narendra Modi and S Jaishankar cover major power centres globally. The visits are aimed at outreach and outcome.
Paper says solar boom exposing storage deficit, with surplus daytime power going to waste as grid struggles to meet evening demand. 'Question has shifted from quantity to timing & flexibility.'
In ep 1859 of CutTheClutter, Editor-In-Chief Shekhar Gupta and Editor (Defence & Diplomacy) Snehesh Alex Philip look at DAC approvals, what it means for India's military and next steps.
The Congress party’s abandonment of nationalism is the most intriguing aspect of its post-2014 politics. The real Congress was never a party of bleeding heart pacifists.
COMMENTS